Is GALE a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

4,780 people get GALE articles and Market Currents by email alert.

Get email alerts on GALE »

HEADLINES:

A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 9 Comments
Galena Targets Cancer Pain Market
Len Zehr • Wed, May 15 • 10 Comments
Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning
Avi Greenberg • Wed, May 15 • 20 Comments
Galena Biopharma: Stock First, Science Second?
Avi Greenberg • Mon, May 13 • 88 Comments
VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting

GlobeNewswire (May 9, 2013)
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
William L. Ashton Joins Galena Biopharma's Board of Directors

GlobeNewswire (May 1, 2013)
Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 24, 2013)
3 Biotechs Targeting Breast Cancer
Equity Options Guru • Thu, Apr 18 • 14 Comments
Galena Biopharma to Present at the 2013 BIO International Convention

GlobeNewswire (Apr 16, 2013)
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments
Galena Pharma: High Hopes For The Shares
Josh Hutheson • Mon, Apr 8 • 9 Comments
Galena Biopharma: Will Developments Continue In 2013?
Amy Baldwin • Wed, Apr 3 • 3 Comments
Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference

GlobeNewswire (Mar 29, 2013)
3 Biotech Stars Ready To Shine
Craig Keolanui • Thu, Mar 28 • 2 Comments
Galena Biopharma: A Small Cap Looking For Revenues
Dutch Trader • Mon, Mar 25 • 3 Comments
The Blitz: Are These Stocks Presenting Upside?
Brian Nichols • Sun, Mar 24 • 19 Comments
A Great Move For Galena Biopharma
Grant Zeng • Wed, Mar 20 • 18 Comments
3 Immunotherapy Companies That Have Learned Their Lessons Well
Teresa Dawn • Mon, Mar 18 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

Galena Targets Cancer Pain Market
Len Zehr • Wed, May 15 • 10 Comments
Galena Biopharma: Stock First, Science Second?
Avi Greenberg • Mon, May 13 • 88 Comments
Galena Pharma: High Hopes For The Shares
Josh Hutheson • Mon, Apr 8 • 9 Comments
Galena Biopharma: Will Developments Continue In 2013?
Amy Baldwin • Wed, Apr 3 • 3 Comments
Galena Biopharma: A Small Cap Looking For Revenues
Dutch Trader • Mon, Mar 25 • 3 Comments
A Great Move For Galena Biopharma
Grant Zeng • Wed, Mar 20 • 18 Comments
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest
Robert Schwartz • Wed, Mar 13 • 150 Comments
Galena: A Small-Cap Biotech Ready To Fly?
Dutch Trader • Tue, Feb 19 • 13 Comments
Galena Biopharma Now Offers Considerable Long-Term Potential
Heather Ingrassia • Mon, Jan 28 • 31 Comments
What Makes For A Market Leading Return In Biotechnology?
Brian Nichols • Tue, Jan 22 • 10 Comments
Galena Removes Financing Risk
The Swiss Trader • Tue, Dec 18, 2012 • 14 Comments
Galena Pulls Back While Analysts Rush To Its Defense
Brian Nichols • Mon, Dec 17, 2012 • 21 Comments
Galena Biopharma: Recent Developments Paint A Picture Of The Year Ahead
Amy Baldwin • Tue, Dec 11, 2012 • 23 Comments
As Galena Teams Up With Teva, Shares Now Possess Some Very Nice Upside Potential
Matt Schilling • Tue, Dec 4, 2012 • 5 Comments
Acadia Pharmaceuticals And Galena Biopharma: What A Difference A Trial Design Can Make
Brian Nichols • Wed, Nov 28, 2012 • 20 Comments
A Fact Based Analysis Of Galena's NeuVax
Rich Steffens • Tue, Nov 20, 2012 • 22 Comments
The Other Side Of Galena Biopharma
PropThink • Thu, Nov 15, 2012 • 77 Comments
Galena Biopharma: Catalysts Have Led Its Stock Higher
Glen S. Woods • Mon, Nov 12, 2012 • 46 Comments
Recent Research And Galena's New Data May Lead To An Advance In Standards Of Care
Brian Nichols • Wed, Oct 31, 2012 • 11 Comments
Assessing Galena Biopharma's Stock Upgrade And Reflecting On Other Upgrades
Brian Nichols • Fri, Aug 24, 2012 • 10 Comments

A Journey To Add Biotech To The Portfolio
Gregory Stuckey • Sat, May 18 • 9 Comments
Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning
Avi Greenberg • Wed, May 15 • 20 Comments
Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers
GuruFundPicks • Tue, May 7 • 8 Comments
3 Biotechs Targeting Breast Cancer
Equity Options Guru • Thu, Apr 18 • 14 Comments
2 Oncology Biotechs For The Future
Bio Matt • Sun, Apr 14 • 10 Comments
3 Biotech Stars Ready To Shine
Craig Keolanui • Thu, Mar 28 • 2 Comments
The Blitz: Are These Stocks Presenting Upside?
Brian Nichols • Sun, Mar 24 • 19 Comments
3 Immunotherapy Companies That Have Learned Their Lessons Well
Teresa Dawn • Mon, Mar 18 • 3 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
Seeking Opportunity: 10 Stocks To Watch Right Now
Brian Nichols • Fri, Mar 15 • 14 Comments
3 Undiscovered Biotech Companies For The Healthcare Investor
William Sterling • Mon, Mar 11 • 31 Comments
Seeking Opportunity: Creating A Plan Of Investment Action
Brian Nichols • Fri, Mar 8 • 22 Comments
A Comprehensive Look At Immunotherapy - Part 2
Brian Nichols • Mon, Mar 4 • 24 Comments
Cancer Biotech Oncothyreon Extremely Undervalued
BuySellShort • Tue, Feb 26 • 36 Comments
The Monday Morning Quarterback
Brian Nichols • Mon, Feb 25 • 12 Comments
'Top Of The Class' Small Pharma Investments For 2013 Part II
Chemistfrog • Thu, Jan 17 • 28 Comments
5 Biotech Stocks To Watch Under $5
Nathaniel Matherson • Mon, Jan 7 • 14 Comments
6 Micro Caps To Add To Your Portfolio For 2013
Jett Dueitt • Thu, Dec 27, 2012 • 10 Comments
4 Small Biotech Stocks That Should Continue With Large Returns In 2013
A John Hodge • Tue, Dec 25, 2012 • 6 Comments
Biotech Under The Electron Microscope: What's In The Pipeline And Lessons To Be Learned
Ryan's View • Sun, Dec 16, 2012 • 9 Comments

There are no Transcripts on GALE.

VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results

GlobeNewswire (May 9, 2013)
Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting

GlobeNewswire (May 9, 2013)
William L. Ashton Joins Galena Biopharma's Board of Directors

GlobeNewswire (May 1, 2013)
Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 24, 2013)
Galena Biopharma to Present at the 2013 BIO International Convention

GlobeNewswire (Apr 16, 2013)
Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference

GlobeNewswire (Mar 29, 2013)
Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain

GlobeNewswire (Mar 18, 2013)
Galena Biopharma Receives 2013 Global Frost & Sullivan Award for New Product Innovation for NeuVax(TM)

GlobeNewswire (Mar 14, 2013)
Galena Biopharma Reports Year-End 2012 Financial Results

GlobeNewswire (Mar 12, 2013)
Galena Biopharma to Present at the 25th Annual ROTH Conference

GlobeNewswire (Mar 11, 2013)
Galena Biopharma to Present at the 7th Annual Bio-Europe International Partnering Conference

GlobeNewswire (Mar 4, 2013)
Galena Biopharma to Present at the 15th Annual Bio CEO & Investor Conference

GlobeNewswire (Feb 5, 2013)
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire (Dec 18, 2012)
Galena Biopharma Announces Public Offering of Common Stock and Warrants

GlobeNewswire (Dec 17, 2012)
Galena Biopharma Presents Final Landmark 60-Month Results From NeuVax(TM) Phase 1/2 Trials at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium

GlobeNewswire (Dec 7, 2012)
Galena Biopharma and Leica Biosystems Announce Partnership to Develop Companion Diagnostic for HER2 Screening in Women With Breast Cancer

GlobeNewswire (Dec 6, 2012)
Galena Biopharma to Present at the Oppenheimer 23rd Annual Healthcare Conference

GlobeNewswire (Dec 5, 2012)
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel

GlobeNewswire (Dec 4, 2012)
Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium

GlobeNewswire (Nov 29, 2012)
Galena Biopharma to Present at the Piper Jaffray 24th Annual Healthcare Conference

GlobeNewswire (Nov 20, 2012)

GALE vs. ETF Alternatives

Company Description

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com. More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 5:39 PM Galena Biopharma (GALE): Q1 EPS of -$0.11 misses by $0.04. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 25, 11:31 AM Needham starts Galena Biopharma (GALE +4.1%) at Buy with $3.50 price target. When administered as an adjuvant, the investment bank says the company's breast cancer vaccine NeuVax shows promise. The vaccine is "one of the leading new product candidates" for adjuvant vaccine therapy which analyst Chad Messer says will "become the standard of care for many cancer types." The company recently acquired Abstral, a sublingual tablet indicated for cancer pain which notched $54M in sales in Europe last year, for sale and distribution in the U.S. Comment! [Healthcare]
Monday, March 18, 11:06 AM Galena Biopharma (GALE +3.4%) gains after saying its entered into an agreement with Swedish drug maker Orexo AB to acquire Abstral Sublingual Tablets for sale and distribution in the United States. Abstral was approved by the FDA in January 2011, and had $54M in sales in Europe in 2012. Under the terms of the agreement, GALE will pay Orexo $10M upfront and $5M within the first twelve months of closing, plus low double digit royalties and one-time milestone payments based on pre-specified net sales. Comment! [Healthcare, On the Move]
Monday, March 18, 9:10 AM Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move]
Wednesday, February 20, 9:10 AM Premarket gainers: NTSP +30%. NVGN +14%. JASO +9%. SINA +8%. GDOT +8%. THLD +8%. RMBS +8%. OMX +7%. ODP +7%. MDRX +6%. GALE +5%.
Losers: HNR -41%. MM -27%. ONCY -12%. GRMN -9%. LIFE -5%. Comment! [On the Move]
Monday, February 4, 9:10 AM Premarket gainers: APKT +23%. RMTI +22%. SONS +10%. PPHM +8%. CCUR +6%. GALE +6%.
Losers: HLF -9%. Comment! [On the Move]
Tuesday, December 18, 2012, 12:45 PM Midday top 10 gainers: BOSC +83%. OPXA +31%. MEIP +30%. ARB +24%. RNIN +21%. VNDA +21%. III +18%. NVGN +16%. SNFCA +14%. GDP +14%.
Midday top 10 Losers: AWRE -23%. CNH -18%. LEI -17%. GALE -17%. LIVE -16%. CIS -14%. GTAT -13%. MNGA -12%. RCMT -12%. SWHC -10%. Comment! [On the Move]
Tuesday, December 18, 2012, 10:35 AM Galena Biopharma (GALE -18.7%) discloses the details of its unspecified secondary offering announced late yesterday, saying it sold 15.2M units for gross proceeds of about $24.3M. The units - consisting of one share of stock and a warrant - priced at $1.60 each. The warrants entitle holders to purchase half a share at an exercise price of $1.90. The company intends to use the proceeds for clinical trials of its breast cancer treatment NeuVax and a trial of its Folate Binding Protein-E39. The company has a current float of around 67.6M shares. Comment! [Healthcare, On the Move]
Tuesday, December 18, 2012, 9:10 AM Premarket gainers: VNDA +26%. ARB +24%. NOK +5%.
Losers: AWRE -24%. GALE -20%. GTAT -14%. RAS -6%. Comment! [On the Move]
Monday, December 17, 2012, 4:45 PM Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering. 1 Comment [Healthcare, On the Move]
Friday, December 7, 2012, 9:30 AM Galena Biopharma (GALE) +7.8% premarket after saying studies of its NeuVax treatment continue to demonstrate excellent safety and efficacy profiles. Comment! [Healthcare, On the Move]
Friday, December 7, 2012, 9:10 AM Premarket gainers: GALE +9%. ACRX +7%.
Losers: AMRN -19%. ABMD -7%. QRE -5%. Comment! [On the Move]
Thursday, December 6, 2012, 8:48 AM Galena Biopharma (GALE) forms a partnership with Germany's Leica Biosystems to use the latter's Bond Oracle HER2 IHC System to help select patients for the Phase III trials of Galena's NeuVax breast cancer treatment. On Tuesday, Galena signed a deal with Teva for the commercialization of NeuVax in Israel. (PR) Comment! [Healthcare]
Tuesday, December 4, 2012, 9:10 AM Premarket gainers: SINO +28%. GALE +14%. FHCO +10%. BIG +7%. OCZ +6%. ALXA +5%.
Losers: GERN -28%. PBY -9%. DRI -9%. SSN -6.4%. PCS -6.4%. Comment! [On the Move]
Tuesday, December 4, 2012, 8:24 AM Galena (GALE) soars 17.2% after signing a deal with Teva (TEVA) for the commercialization of its NeuVax breast cancer treatment in Israel. While financial terms weren't disclosed, Teva will make significant royalty payments to Galena on future sales. Israel will be the location of at least four sites for Phase 3 trials of NeuVax. Comment! [On the Move, Healthcare]
Wednesday, November 28, 2012, 10:37 AM Galena Biopharma (GALE +7.7%) jumps this morning after Aegis Capital initiated the shares with a Buy and a $6.00 price target. Aegis says that GALE has developed a novel approach to combating the recurrence of breast cancer in patients with minimal residual disease. The firm's lead candidate, NeuVax, is a peptide vaccine derived from a protein that is the target of several widely used breast cancer treatments. It's currently conducting Phase III trials and is slated to report interim data in late 2013. Comment! [Healthcare, On the Move]

Ron Reed
What is today's issue with $GALE? Just no news causing a 14% drop? Looks like things have not changed for $GALE at all...
May 2, 4:34 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days.
May 2, 6:22 PM
• !Report Abuse
jsiebel720: Motley Fool article
May 2, 8:24 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
$GALE finally paying off a bit, up 49% since purchase.
Apr 30, 8:04 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

drjad123
What's up with $GALE ?
Apr 30, 2:01 PM
Reply (1)

• !Report Abuse
View all 1 replies
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
May 2, 12:44 PM
• !Report Abuse
Add a reply...

140 characters

Bio Matt
Current biotech/pharma portfolio: $ALXA $SRPT $AMBS $GALE $ONCS $RAFA $MRK
Apr 13, 8:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

swing54
$GALE Institutional Investors (90% of market participants) are on buying side to prepare for the run with the Institutional Traders!
Apr 3, 4:59 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

swing54
$GALE The Institutional Action is on the buying side. The Institutional Investors (90% of market participant) don't move the price! We waite
Apr 3, 4:59 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

richardod
started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back buying ATHX do not see more winners - $CUR? ++?
Mar 28, 5:48 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r
Mar 12, 10:29 AM
Reply (3)

• !Report Abuse
View all 3 replies
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
Mar 12, 9:31 PM
• !Report Abuse
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
Mar 13, 9:51 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Ron Reed
What is today's issue with $GALE? Just no news causing a 14% drop? Looks like things have not changed for $GALE at all...
May 2, 4:34 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Ran too far too fast is my guess. See CPRX get shorted like crazy after it doubled in three days.
May 2, 6:22 PM
• !Report Abuse
jsiebel720: Motley Fool article
May 2, 8:24 PM
• !Report Abuse
Add a reply...

140 characters

drjad123
What's up with $GALE ?
Apr 30, 2:01 PM
Reply (1)

• !Report Abuse
View all 1 replies
Owen Bernard: Not sure you found any answers - most interesting was a new B.O.D. joined $GALE, William L. Ashton. Definitely an attention getter.
May 2, 12:44 PM
• !Report Abuse
Add a reply...

140 characters

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

Robert Schwartz
Galena Biopharma ($GALE): What to know before you invest http://seekingalpha.com/p/z54r
Mar 12, 10:29 AM
Reply (3)

• !Report Abuse
View all 3 replies
Robert Schwartz: They are missing quite a bit. Take a look at their characterization of the Phase-I/II-data, it is way off base.
Mar 12, 9:31 PM
• !Report Abuse
isafin: So, the recent wobble of the stock price can be substantiated by other than speculative trends reasons. Thank you.
Mar 13, 9:51 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Rich Steffens
If I had free $, I'd start my position in $GALE, especially after learning from COL GEP of AF's inaccuracies.
11/27/12
Reply (12)

• !Report Abuse
View all 12 replies
Ron Reed: week later when it falls back down. Great idea company just no sense in how to turn it into money for the investor.
12/30/12
• !Report Abuse
Rich Steffens: 11/27 AF made false claims. GALE closed @ 1.58. A trade long was born. 11/29 @ 2.04. 12/04 @ 2.24. Take profit, when so high, add later.
12/31/12
• !Report Abuse
Add a reply...

140 characters

z28gator
Anyone know why $GALE is down today?
11/27/12
Reply (1)

• !Report Abuse
View all 1 replies
smokeyRose: Because it's A Bio-Pharm. They Have No Stability at all.........Unless of course someBody on the inside Knows about Drug approval and or Dis
11/27/12
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
"GALE" running nicely today, bought on a low yesterday, love days like this..
11/13/12
Reply (2)

• !Report Abuse
View all 2 replies
Noreika: Nice work!
11/13/12
• !Report Abuse
LEIGHDIST: thanks Norika
11/23/12
• !Report Abuse
Add a reply...

140 characters

measureupnow
Anyone know why GALE is tanking today?
11/12/12
Reply (1)

• !Report Abuse
View all 1 replies
Todd Theman: New article from PropThink out this morning
11/12/12
• !Report Abuse
Add a reply...

140 characters

EvrClrx311
Wish I had bought more than just 3000 shares back when GALE was trading around 50 cents.
10/31/12
Reply (2)

• !Report Abuse
View all 2 replies
EvrClrx311: I'm sure in another year I'll be saying "wish I had owned more than just 5000 shares when GALE was at $2"
10/31/12
• !Report Abuse
NYorkerinUT: You just never know sometimes. I was considering GALE when it was under a buck, but thought it might get de-listed or reverse split.
11/1/12
• !Report Abuse
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

aumeoli
GALE ready for takeoff? I am in at $1.76
9/5/12
Reply (4)

• !Report Abuse
View all 4 replies
Robbster: Good move, good entry point. Agree with EvrClrx, is a long play.
9/10/12
• !Report Abuse
aumeoli: Agreed! But it is still playing in a range. Show me volume and >$2.50 and I will really like it. Lot of time before approval
9/10/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/28/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: http://bit.ly/RntWCr
8/28/12
• !Report Abuse
DAG1996: thanks for sharing that.
8/28/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/27/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: http://bit.ly/RntWCr
8/27/12
• !Report Abuse
Add a reply...

140 characters

manuyc
I'm a newbi! Had a question on GALE is it a good time to put more money into it? Thank you.
6/23/12
Reply (4)

• !Report Abuse
View all 4 replies
Ron Reed: I would hold off until Earnings come out. I think they will be in line or negitive and the stock should drop and then rebound.
8/9/12
• !Report Abuse
mux: In my honest opinion, I truly feel this will be a blockbuster. The price is a bargain right now. News can come out at any time
8/13/12
• !Report Abuse
Add a reply...

140 characters

GALE Galena Biopharma, Inc.

GALE

Galena Biopharma, Inc.